Menopause Drug A Priority For Astellas
Fast Track For Fezolinetant
The Japanese group has used a priority review voucher for fezolinetant to move further ahead of Bayer’s elinzanetant as it seeks regulatory approval to bring a non-hormonal therapy for menopausal symptoms such as hot flashes and night sweats to market.
You may also be interested in...
Women’s Health Still Key to Bayer Despite Early Research Shift
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
Astellas CEO Yasukawa On Gene Therapy Challenges, Deal Strategies
Despite facing two clinical holds for its gene therapy candidates, Astellas is committed to proceeding with R&D projects in this modality. Outgoing CEO Kenji Yasukawa says technical challenges have motivated the firm's recent deals with academia and bioventures, and also provided updates on other key pipeline assets in the second part of this exclusive interview with Scrip.
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.